The PI3K pathway has been shown to be activated in a mouse model of BRCA1-mutated breast cancer and the combination of olaparib and BKM120 was synergistic and as such, related to improved efficacy, as compared to either agent alone [65]. Here, BRCA1 is linked to breast cancer.